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Dosage of pain rehabilitation programs:
a qualitative study from patient and
professionals’ perspectives
Michiel F. Reneman1*, Franka P. C. Waterschoot1, Elseline Bennen2, Henrica R. Schiphorst Preuper1,
Pieter U. Dijkstra1,3 and Jan H. B. Geertzen1
Abstract
Background: There is a large and unexplained practice variation in prescribed dosages of pain rehabilitation programs
(PRP), and evidence regarding the optimum dosage is unknown.
Methods: To explore perspectives of patients and rehabilitation professionals regarding dosages of PRP an explorative
qualitative research design was performed with thematic analysis. Patients and rehabilitation professionals were recruited
from three rehabilitaton centers in the Netherlands. A purposive sample of patients who completed a PRP, with a range
of personal and clinical characteristics was included. Rehabilitation professionals from all different disciplines,
working within multidisciplinary PRP for a minimum of two years, for at least 0.5 fte were included. Individual
semi-structured interviews were conducted with 12 patients undergoing PRP, and three focus groups were formed
with a total of 17 rehabilitation professionals involved in PRP.
Results: All patients were satisfied with received dosage. Factors important in relation to dosage of PRP were categorized
into patient related characteristics (case complexity from a biopsychosocial perspective) to treatment related
characteristics (logistics and format of the program, interaction between patients and professionals), and external factors
(support from others, costs, traveling distance and injury compensation). Professionals concluded that dosage
was currently based on historical grounds and clinical expertise.
Conclusion: Patients and professionals from different centers considered the same factors related to dosage
of PRP, but these considerations (from patients and professionals) led to different dose choices between centers. PRP
dosage appeared to be mainly based on historical grounds and clinical expertise. The insights of this study could assist
in future research regarding optimum dosage of PRP and rehabilitation programs in general.
Keywords: Pain rehabilitation programs, Dosage, Qualitative study, Chronic pain
Background
Multidisciplinary Pain Rehabilitation Programs (PRPs) are
recommended to treat patients with chronic musculoskel-
etal pain (CMP) [1, 2]. These PRPs, based on the biopsy-
chosocial model, aim to decrease disability and optimize
participation of patients with CMP. A systematic review
showed that PRPs have a moderate, but consistent, posi-
tive effect on disability and pain, compared to usual care
or physical treatment programs for patients with chronic
low back pain [3]. PRPs result in better self-management
of pain and disability, and a reduction in healthcare
utilization in treated patients was found, which may
contribute to a decrease of direct and indirect costs
over the long term [4].
Although effective, PRPs are relatively expensive. The
multidisciplinary characteristics, as well as the high
number of contact hours and total duration of PRP, pro-
vide relatively high direct costs and travel expenses for
the patients. Dosage of PRP includes the total duration,
the total number of contact hours, and intensity of treat-
ment (number of contact hours per week). Differences
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in the dosage of PRP may lead to differences in direct
and indirect costs. Choices for dosage and how dosage is
established for an individual patient is unknown. A re-
cent systematic review showed that dosage of PRP has
never been studied as a primary aim and the optimum
dosage of PRPs is currently unknown [5]. The studies
included in that review differed in terms of dosage (total
duration, from weeks to months, and regarding contact
hours, from fewer than 10 to over 100 h) and effect.
Better understanding of variables that are taken into
account when deciding for a particular dosage could lead
to better and more efficient patient care, which will benefit
patients, rehabilitation facilities, insurers and employers.
This study aimed at exploring perspectives of patients and
rehabilitation professionals to acquire insight into factors
that may contribute to dose choices of multidisciplinary
outpatient PRP. In addition, this study aimed at examining
the argumentations underlying choices in dosage of PRPs
in three rehabilitation centers in the Netherlands.
Methods
A study using an exploratory qualitative design with the-
matic analyses was conducted to gain in-depth information
about the perspectives of patients and rehabilitation profes-
sionals involved in PRPs regarding the dosage of these pro-
grams. The study was performed in three rehabilitation
centers in the Netherlands. These centers were selected
because of their differences in dosage, while patient
characteristics of these centers are similar [6]. Individ-
ual semi-structured interviews with patients who had
completed a multidisciplinary PRP, as well as focus
groups with professionals working in multidisciplinary
PRP, were performed. The medical ethics committee of
the University Medical Center of Groningen (UMCG)
granted a waiver for this study. All participants signed
informed consent for participation, digital recording and
the use of data.
Participants
A purposive sample of patients was included from three
rehabilitation centers in the Netherlands with the task
to develop, innovate and evaluate PRPs: Adelante in
Hoensbroek (RC1), located in the south; Roessingh in
Enschede (RC2), located in the east and the Center of
Rehabilitation of the UMCG (RC3), located in the north.
The sampling strategy aimed to include patients who com-
pleted a PRP, with a range of personal and clinical charac-
teristics: age, disability status, gender, working status, and
dosage received. PRP should have been completed for at
least two weeks. The second author contacted potential
participants (recruited by the contact person of the rehabili-
tation center) via telephone to check their willingness to
participate in the study and to plan the interview. They
received written information about the purpose of the
interview.
The contact person of the centers selected rehabilita-
tion professionals from the rehabilitation centers. They
participated in the focus groups, provided that they were
working within the area of multidisciplinary PRP for a
minimum of two years, for at least 0.5 fte. We aimed to
include rehabilitation professionals from different disci-
plines involved in PRPs (i.e. occupational therapist/physio-
therapist/psychologist/physiatrist). These rehabilitation
professionals should be involved in determining the indi-
vidual dosages of the program for the patient.
Data collection
Data were collected between May and September 2014.
A total sample of 15 patients was planned for the inter-
views, five patients from each rehabilitation center, with the
expectation of reaching data saturation. A semi-structured
interview scheme was constructed Additional file 1 for pa-
tients using open questions enabling reflection about expe-
riences and perceptions on dosage of treatment received.
The interview started with questions about the total dur-
ation and intensity of PRP, followed by questions regarding
personal experiences and perceptions of treatment dosage,
such as: “what did you like and dislike about the duration
and intensity of the program” and “which factors, in your
opinion, influence dosage of PRP?”. Also patients’ opinions
regarding the relationship of dosage to return to work and
personal and general costs were asked. Face-to-face inter-
views were performed at the rehabilitation center where the
patient was treated. The interviews were scheduled for
60 min and were audio recorded. Prior to this study, an
interview was pilot tested, which led to refinements in the
setup of the interview and questioning technique.
For the focus group meetings, a minimum of five re-
habilitation professionals of different disciplines per
center were invited in order to achieve variation in per-
spectives on PRP dosage per rehabilitation center.
Meetings were planned for 90 to 120 min and were
audio recorded. An interview scheme was constructed,
aiming to gain insight into the line of reasoning under-
lying dosage choices, as well as rehabilitation profes-
sionals’ perspectives on optimum dosage of PRPs.
All patient interviews and focus group meetings in
Adelante and Roessingh rehabilitation centers were
led by one author (FW), who has over 10 years of ex-
perience as an occupational therapist in pain rehabili-
tation. Because she was closely acquainted with the
rehabilitation professionals at UMCG, a psychologist
with experience in chronic pain treatment but who
was not involved in the treatment of the patients led
this focus group. Another author (EB) assisted in all
focus groups.
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Data analysis
Interviews and focus groups were audio recorded and
transcribed verbatim by two authors (FW and EB). Tran-
scripts were imported into ATLAS.ti, version 5.2, to
analyze data. Thematic analysis was considered as the
appropriate approach for identifying, analyzing and
reporting factors related to dosage of PRP [7]. Because
of the lack of evidence regarding dosage of rehabilitation
programs, especially for PRP aimed at behavior change
[5], it was not possible to provide a detailed theoretical
framework. Initially, both authors conducted the induct-
ive coding of the interviews and a third researcher inde-
pendently validated the codes. All codes and quotations
were re-analyzed, merged, and renamed.Data saturation
was assumed when no new themes emerged from a con-
secutive interview or focus group.
Results
Participants
In total, 13 patients were interviewed and 12 interviews
were analyzed. Initially, five patients per center were
planned, two dropped out because of logistics problems
and one was excluded because the audio was impossible
to transcribe. Seventeen rehabilitation professionals par-
ticipated in the focus groups (Adelante in Hoensbroek: n =
5, Roessingh in Enschede: n = 5, Center for Rehabilitation
of the UMCG in Groningen: n = 7). Different disciplines
participated: occupational therapists (n = 4), physiothera-
pists (n = 3), movement teacher (n = 1), psychologists
(n = 4), social workers (n = 2) and physiatrists (n = 3).
The characteristics of participants are described in Table 1.
Data saturation was reached for patient interviews and
focus groups for rehabilitation professionals.
Factors related to dosage
Different codes related to dosage of PRP were de-
rived from the interviews and focus groups. A total
of 36 codes were categorized as patient-related fac-
tors (n = 11), treatment-related factors (n = 17) or external
factors (n = 9). In addition, the codes were arranged as
“shared” (indicating that they were mentioned by patients
and rehabilitation professionals), “patients” (factors men-
tioned by patients only), and “rehabilitation professionals”




Both patients and rehabilitation professionals mentioned
case complexity of a patient as an important factor re-
lated to dosage of PRP as well as an important issue to
take into account for indication of dosage of PRP. Both
patients and rehabilitation professionals described char-
acteristics that affect dosage of PRP, such as the general
status (the level of physical condition or the degree of
experienced disability), as well as the degree of insecurity,
self-understanding, motivation and ability to change
behavior, in addition to the expectancies patients have re-
garding treatment and treatment results. (Patient 3 (P3)):
“It depends on what is going on with someone. Is he trauma-
tized? Does he want to talk about it? Is he able to manage
his problems? Does he have some self-understanding; does
he know what his problem is?”
Both patients and rehabilitation professionals men-
tioned that PRP requires focusing on yourself. Patients
and rehabilitation professionals involved with both high
and low PRP dosages mentioned this focus as being related
to dosage. A patient (P7) who underwent semi-inpatient
PRP described: “The inpatient format of treatment was a
good experience. It was quite intense, but actually very good
because you really have to focus on yourself. If I would have
been at home, I would have been distracted by all the things
you have to do at home”. Focusing on oneself and on the
treatment was also mentioned by a patient (P9) as motiv-
ation for preferring twice a week PRP instead of once a
week: “Yes, two times a week, then you are really engaged
with the treatment. Treatment only once a week…. well,
then a whole week is in between…”. Rehabilitation profes-
sionals mentioned that a patient being able or motivated to
Table 1 Characteristics of participants and PRP dosage
RC1 RC2 RC3
Patients (n = 4) (n = 4) (n = 4)
Age mean (SD) 42 (16) 37 (11) 53 (7)
Female % 75 100 100
Duration of pain n
1 to 2 years 0 1 2
2 to 5 years 2 0 0
> 5 years 2 3 2
Initial PDI score mean (SD) 27 43.3 (14.2) 31.5 (16.4)
Missing n 3 0 0
Rehabilitation professionals (n = 5) (n = 5) (n = 7)
Age mean (SD) 41 (6) 43 (9) 39 (6)
Female % 60 80 71
Years of experience in PRP mean (SD) 7.6 (4.7) 9.0 (5.6) 7.4 (5.5)
PRP
Range in total duration (wks)
Assessment 3 1 to 2 1 to 2
Treatment 12 3 to 36 8 to 20
Range in contact hours
Assessment 30 2 3
Treatment 120 10 to 150 30 to 70
PDI Pain Disability index, PRP Pain Rehabilitation Program, RC1 Adelante in
Hoensbroek, RC2 Roessingh in Enschede, RC3 Center for Rehabilitation of the
UMCG in Groningen
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focus on oneself results in being motivated to follow the
prescribed dosage of PRP. In some cases, for example
(Therapist 13 (T13)) “if a patient is overloaded”, being able
to focus on oneself may be an important factor to consider
while determining dosage.
Acceptance of pain is related to the content of PRP.
Participants mentioned that PRP contributed to the ac-
ceptance of pain and that patients need time to go
through a process of acceptance (P4): “I think the mini-
mum duration of PRP should be 12 weeks. Especially be-
cause you experience a process of change in which you
need time… time to make a start, because after those 12
weeks you still need to go on for yourself”.
For patients able to self-manage pain and disabilities,
participants suggested a lower dosage of PRP, as compared
to an unable patient. A rehabilitation professional in a focus
group (T16) described: “Sometimes the minimum dosage of
PRP is just one hour of intake. There are patients who just
need some explanation to self manage their lives again. Be-
ing able to self manage pain is related to patient character-
istics and behavior, the way people are, and whether they
are able to cope with their pain and disabilities themselves”.
To apply lessons learned into practice, patients need
time. (P9) “It is a process which requires time, 6 or 8
weeks… well, that’s quite short…. You need to be aware
of things, you have to practice, adjust and adopt”. Need-
ing time to apply lessons learned was mentioned with
regard to intensity (contact hours per week) and the re-
duction of intensity of contact hours during PRP. (T13):
“At the end of the program, reducing the intensity of the
program (fewer days or fewer contact hours per week),
could support the process of putting the lessons learned
into practice”.
Factors from patients only
Assertiveness was mentioned by patients with regard to
the ability to stand up for themselves. This code is part
of the goals and content of PRP and therefore patients
mentioned this in relation to needing a lower dose when
patients are already able to stand up for themselves..
(P8) “I had to learn to set boundaries. My day was fully
planned and I used to do whatever I was told, which re-
sulted in being exhausted at the end of the day”. Some
patients reported that they needed support during times
Table 2 Overview of codes per category
Factors mentioned
by patients only













Apply lessons learned into practice
Team & treatment related factors Having time and opportunity
to explore
Waiting time –
Saturation Clarity about dosage and time plan Lack of evidence
Expertise of the team Individually tailoring Prediction of dosage of PRP
Shared decision making Timing to finish PRP





External factors Support from environment Direct costs Travelling time
Indirect costs Format of treatment
Investment for the future Injury compensation
Personal and work factors Test results or other treatments
Reneman et al. BMC Musculoskeletal Disorders  (2018) 19:206 Page 4 of 8
of relapse, which may contribute to a decision to extend
the program. (P2): “Everything was going well; I also felt
it that way. However, I did not have the feeling that I
was ready. I was afraid that I would relapse and that
was why I needed some sessions”.
Factors from rehabilitation professionals only




Waiting time before and during treatment can influence,
in a negative or positive way, the general status of a patient
at the start of treatment, therefore having an influence on
the dose of PRP. One patient (P1) described how she was
able to turn the negative result of the waiting time into a
positive action: “I had to wait for a long time before start of
PRP. For me personally, it has led to an increase of pain
and I became depressed. Consequently, I realized I had to
do something and I started doing things on my own”. Most
patients knew the total duration of PRP beforehand. Pa-
tients were satisfied with this clarity about dosage and time
plan for PRP: (P4) “I compare it with knowing when to go
on holidays: the last week at work you are really into holi-
days. With treatment, it is the same – you have a set goal to
work on in time”. Nevertheless, besides structured dosages
providing this clarity, participants emphasized that the pos-
sibility of individually tailoring dosage to their needs is
important. The individually tailored dosage is also related
to shared decision-making. Patients and rehabilitation
professionals attached value to shared decision-making in
terms of PRP dosage. Good contact between patient and
rehabilitation professionals supported treatment and
therefore could reduce dosage: (P11): “You need to have a
connection with your rehabilitation professionals; otherwise
you will not make any progress”. However, too many
changes in rehabilitation professionals during treatment
can impede the connection, and therefore the process, be-
cause: “you have to tell your story again and again”. Related
to this code, patients and rehabilitation professionals men-
tioned that good interdisciplinary functioning of the team
supported efficiency and could reduce PRP dosage. (P9): “I
experienced that everyone knew who I was and what I
needed. Everyone had read all reports and you did not need
to tell the same stories”. Both patients and rehabilitation
professionals made it clear that dosage of PRP was strongly
related to the content of treatment, treatment goals and
the format of treatment (e.g. inpatient versus outpatient).
Factors from patients only
Most patients had the experience of having time and
opportunity during PRP to explore themselves and reach
their goals. However, some patients also experienced this
as a problem when the frequency was reduced from five
days to two days per week. “Content became more inten-
sive, everything was put together in two days and every-
thing had to go faster…I had to hurry….”. Some patients
denoted that towards the end of treatment, saturation of
treatment content occurred. Therefore, they suggested
that retrospectively, the dosage could have been reduced.
(P2): “At a certain moment, you are done with it”. Patients
stated that they trust the expertise of the team, both with
regard to the content of treatment as well as a determin-
ation of dosage and when decisions are made regarding
the need to prolong or reduce PRP dosage. (P1): “I
thought, well if that is the success of the treatment, then
I am going to do it that way”.
Factors from rehabilitation professionals only
The focus groups revealed that there was a lack of
published evidence for the delivered doses of PRP.
(T15) “These programs have been developed and adapted
over the years based on skills acquired by the team, and
developments such as group based treatments. This pro-
vides certain components in the program. This is what we
have; we did not question ourselves if it is necessary for
patients”. Additionally, with that lack of evidence, it is
hard to predict dosage of PRP and to decide when the
timing is right to finish PRP: “It is a difficult decision, at
what point a patient is ready, and to reach consensus
about this within the team and also with the patient…. ”.
External factors
Shared factors
The majority of participants stated that financial factors
should not influence dosage of PRP. Patients could im-
agine that direct costs that patients have to pay them-
selves, like travel costs, could be of concern for some
patients, although they did not experience this problem
themselves. (P11): “It is regrettable if your own develop-
ment depends on a few Euros extra per month”. Direct
costs of treatment and indirect costs, for example those
related to returning to work, should not influence treat-
ment because patients saw the costs of treatment as an
investment in the future: (P9): “Well, I think, on the
longer term, if treatment works, you save money. It also
applies for work: if my boss did not allow me time for this
treatment, I might not yet be at work for 100%”. Per-
sonal and work factors could have a positive or nega-
tive influence on the opportunity to receive treatment,
and therefore could influence the satisfaction or choice
for dosage of PRP. Some patients had to adjust their ac-
tivities at home to their treatment: (P11): “On treatment
days, I did not have the energy to do things at home. I
was happy I made the choice to delegate the household
tasks. The days at home I had time to do things with my
children and husband”. A rehabilitation professional
Reneman et al. BMC Musculoskeletal Disorders  (2018) 19:206 Page 5 of 8
mentioned that sometimes, dosage of treatment can be
adjusted to work or personal situations: “If patients are
not able to organize the required dosage of two times a
week and they have strong reasons, we sometimes decide
to reduce frequency of treatment to once a week”.
Factors from patients only
Patients perceived support from environment (e.g. part-
ner, colleagues, employer) as a positive factor because it
can contribute to better results and may lower dosage,
and thus helped with completing PRP successfully. Lack
of support could negatively influence the results of the
program and may lead to extension of PRP.
Factors from rehabilitation professionals only
In the focus groups, rehabilitation professionals men-
tioned that patient travel time could influence the choice
of the offered format of treatment, therefore influencing
the dosage of PRP. “This center is a center of expertise re-
garding pain rehabilitation, so patients come from across
the province, which makes outpatient rehabilitation not
appropriate”. If the patient received injury compensa-
tion, it sometimes can impede progression in func-
tional improvements. Therefore, rehabilitation professionals
stated that in some cases, this could be a reason for not
starting PRP or for stopping it prematurely. Test results or
other treatments can also influence the dosage of PRP:
“More often you see a sort of intermediate treatment
if patients need other treatments, like EMDR ….. Or if
test results are not available; waiting for these results
causes delay” (EMDR is the abbreviation for Eye Move-
ment Desensitization and Reprocessing; trauma treatment).
Differences and similarities
Interviews and focus groups were performed in three re-
habilitation centers across the Netherlands. All centers
offered multidisciplinary PRP for patients with CMP.
Although factors were similar for all centers, dosages
differed per center.. All patients, in general, mentioned
being satisfied with the received dosage, although some
had suggestions for improvements related to dosage of
PRP. Rehabilitation professionals reported that they sup-
ported the choices for current dosages of PRP; however
they also had suggestions for improvements and implica-
tions for further research in order to eliminate the lack
of evidence for an optimal dosage of PRP.
Discussion
As part of an ongoing exploration into factors related to
optimizing dosage decisions of PRP, this study provides
insight into perspectives of patients and rehabilitation
professionals that in- or explicitely feed PRP dosage de-
cisions. Factors important in relation to dosage of PRP
were patient related characteristics, treatment related
characteristics and external factors. In the patient related
factors case complexity from a biopsychosocial perspec-
tive was important in determining dosage. Regarding
treatment related characteristics, logistics played a role,
including referral factors, the format of the program was
considered and interactions between patients and pro-
fessionals were taken into account. As external factors,
support from others, costs, traveling distance and injury
compensation were taken into account when deciding
on dosage. Despite agreements in factors deemed im-
portant to establish dosage, the actual dosages differed
to a large extent. For example, in general, patients need
clarity about their dosage of the PRP at the start of pro-
gram, but they would like to have the opportunity to
adapt the dosage to their individual needs during PRP, in
consultation with their rehabilitation professionals. Pa-
tients and rehabilitation professionals mentioned that
personal characteristics, such as motivation and ability
to change, general status of a patient, acceptance, and
self-understanding, are taken into account when determin-
ing dosage. No explicit reasons for differences in choices of
dosage were expressed during the focus groups, which
suggests that PRP dosage choices are based on historical
grounds, economics, routine and clinical expertise. This, in
turn, can be explained from the absence of evidence to
guide clinicians [5]. It seems that each rehabilitation center
has its own ‘baseline-dose’, which forms a basis for choices
to extend or shorten the PRP while taking into account
factors mentioned in this study. These factors were similar
between professionals of different centers.
Treatment outcome is the sum of specific and non-
specific treatment effects. Specific effects are those effects
that are unique for the treatment, for instance increase of
grip strength after grip strengthening exercises, or behav-
ioral modification after cognitive behavioural treatment.
Non-specific effects are effects that are common for differ-
ent types of treatments. These effects are related to for
instance expectancy of results, a shared biopsychosocial ap-
proach in delivering PRP by team members, relationship
factors like warmth, encouragement, listening but also to
setting of the treatment. The factors mentioned in this
study are linked to specific or non-specific effects. Content
and format of treatment, and external factors (e.g. direct
and indirect costs, investment in future, personal and work
factors, support, test results) are factors that are taken into
account when deciding for a certain dosage, and influence
satisfaction with dosage. These factors could explain part of
the differences in choices of the offered PRP dosage. How-
ever, the results of this study showed that these factors are
not sufficient to explain the difference in dosage between
centers.
It is hypothesized that in the absence of evidence re-
garding dosage of PRP, as mentioned in the focus groups,
all rehabilitation centers made different choices regarding
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dosage. Current choices are in part based on content and
dosage at the time of developing the PRP. Over time,
dosage was adapted because of changes in society, costs,
experiences, and new insights related to content or format
of treatment. At present, however, no published evidence
can support or refute the choices of dosage and therefore,
rehabilitation professionals are not able to rationally
choose optimum dosage of PRP.
Strengths and limitations
Analyzing factors associated with dosage using a qualitative
method from the perspective of patients and rehabilitation
professionals is considered a strength of this study because
it is the first study providing an overview of factors related
to dosage from patient and professionals’ perspectives. Tak-
ing into account three leading PRPs with different dosages
and similar content across the Netherlands is a strength
because this provides insight into the differences and simi-
larities regarding perspectives of dosage, resulting in similar
factors regardless of dosage varieties. Although this study
was performed in three centers, it focused solely on centers
in the Netherlands, limiting generalization to PRPs per-
formed in other countries. The qualitative nature of this
study resulted in perspectives that cannot simply be
generalized to all other groups of patients and rehabili-
tation professionals involved in PRPs. As this was a first
and explorative study, many topics were covered and
perspectives were raised during the interviews. While
this methodology has lead to a broad range of factors
that may be considered to decide on an optimum PRP
dose, the downside is its lack of depth of these perspec-
tives. Future studies should build on the results of this
study to further explore these factors.
Recommendations
This study is an initial exploration of the perspectives of
patients and rehabilitation professionals regarding PRP
dosage. It resulted in an overview of factors that can be
used for future research and clinical practice regarding
determining PRP dosage. Clinical practice might be im-
proved by taking these factors into account when con-
templating on dosage and making more explicit dosage
decisions with a patient, being a mutual decision be-
tween professional and patient, geared towards overall
success of PRP.
Conclusions
In conclusion, this study shows that, although dosage of
PRP differed, patients and rehabilitation professionals
mentioned similar themes that influence dose choices:
patient related characteristics (case complexity from a
biopsychosocial perspective), treatment related charac-
teristics (logistics and format of the program, interaction
between patients and professionals), and external factors
(support from others, costs, traveling distance and injury
compensation). In absence of published evidence, dif-
ferences in choices of PRP dosage appear mainly based
on historical grounds and clinical expertise. Therefore,
research is needed to guide choices of optimum PRP
dosage.
Additional file
Additional file 1: Semi-structured interview patients. Focus group
interview rehabilitation professionals. (DOCX 16 kb)
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